Whoop expands advanced labs offering to non-members, adds Grail’s multi-cancer detection test to lineup
Advanced Labs includes insights on cardiovascular, metabolic and inflammatory health through comprehensive, clinician-reviewed blood testing.
Whoop, the fitness wearable company, is expanding its Advanced Labs testing to non-members, alongside adding Grail’s multi-cancer detection test to its offerings. Advanced Labs combines blood testing by Quest, clinician-reviewed results, AI-driven insights, and personalized recommendations. The testing covers cardiovascular, metabolic, and inflammatory health, with 80% of users discovering meaningful health findings and half receiving results that may require follow-up with a healthcare provider.
The aim is to help individuals move beyond data collection to understanding health insights, identifying focus areas, and having clearer conversations with healthcare providers. Advanced Labs starts at around $150, with plans for members varying based on test frequency. Additionally, Whoop is incorporating Grail’s multi-cancer early detection test, available at nearly 2,000 Quest locations, for both members and non-members.
Grail’s vice president of medical affairs, Megan Hall, expressed excitement about partnering with Whoop to make multi-cancer early detection more accessible. As of now, Whoop has over 3 million members globally and has raised $575 million in funding, leading to a $10.1 billion valuation.
Written by urgent.news from Fierce Healthcare's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
